- Home
- QCRH vs PRAX Comparison
QCRH vs PRAX Comparison
Compare QCRH & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- PRAX
- Stock Information
- Founded
- QCRH 1993
- PRAX 2015
- Country
- QCRH United States
- PRAX United States
- Employees
- QCRH N/A
- PRAX N/A
- Industry
- QCRH Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- PRAX Health Care
- Exchange
- QCRH Nasdaq
- PRAX Nasdaq
- Market Cap
- QCRH 1.4B
- PRAX 1.5B
- IPO Year
- QCRH 1993
- PRAX 2020
- Fundamental
- Price
- QCRH $80.70
- PRAX $70.54
- Analyst Decision
- QCRH Buy
- PRAX Strong Buy
- Analyst Count
- QCRH 3
- PRAX 9
- Target Price
- QCRH $76.00
- PRAX $146.33
- AVG Volume (30 Days)
- QCRH 89.8K
- PRAX 309.5K
- Earning Date
- QCRH 01-22-2025
- PRAX 03-04-2025
- Dividend Yield
- QCRH 0.30%
- PRAX N/A
- EPS Growth
- QCRH 6.88
- PRAX N/A
- EPS
- QCRH 6.88
- PRAX N/A
- Revenue
- QCRH $341,805,000.00
- PRAX $1,605,000.00
- Revenue This Year
- QCRH N/A
- PRAX N/A
- Revenue Next Year
- QCRH $10.78
- PRAX N/A
- P/E Ratio
- QCRH $11.73
- PRAX N/A
- Revenue Growth
- QCRH 5.07
- PRAX N/A
- 52 Week Low
- QCRH $54.37
- PRAX $33.01
- 52 Week High
- QCRH $96.08
- PRAX $86.93
- Technical
- Relative Strength Index (RSI)
- QCRH 44.87
- PRAX 46.51
- Support Level
- QCRH $75.51
- PRAX $60.07
- Resistance Level
- QCRH $81.65
- PRAX $71.21
- Average True Range (ATR)
- QCRH 1.83
- PRAX 4.07
- MACD
- QCRH 0.30
- PRAX -0.79
- Stochastic Oscillator
- QCRH 72.69
- PRAX 49.11
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.